Jackie and everyone,
Affluence doesn't really come into it - we have budgets too and we are
concerned with getting value as we ultimately have to prove we get a
business benefit from the money we spend.
I can't comment on our Nature deal as I did not negotiate this; I can say
that we have elected not to take a particular core title from one particular
publisher as it was too expensive to justify.
This does beg the question: if "affluent" companies are thinking twice about
purchasing online titles, maybe it's simply a question of the products being
too expensive full stop, rather than aiming them at a particular market ?
Phillip
---------------------------------------
Phillip Ruston, Systems Librarian
Research Library (ipc 855)
Pfizer Global Research & Development, Sandwich Laboratories
Ramsgate Road
Sandwich
Kent
United Kingdom
CT 13 9NJ
http://www.pfizer.co.uk
Email: [log in to unmask]
UK Contact:
Tel: 01304 641140
Fax: 01304 658300
International:
Tel: +44 1304 641140
Fax: +44 1304 641140
LEGAL NOTICE
Unless expressly stated otherwise, this message is confidential and may
be privileged. It is intended for the addressee(s) only. Access to this
e-mail by anyone else is unauthorised. If you are not an addressee, any
disclosure or copying of the contents of this e-mail or any action taken
(or not taken) in reliance on it is unauthorised and may be unlawful. If
you are not an addressee, please inform the sender immediately.
Pfizer Limited is registered in England under No. 526209 with its
registered office at Ramsgate Road, Sandwich, Kent CT13 9NJ
-----Original Message-----
From: Bower, Jackie [mailto:[log in to unmask]]
Sent: 07 February 2001 09:47
To: [log in to unmask]
Subject: Re: Nature
PFIZER GLOBAL RESEARCH AND DEVELOPMENT
----------------------------------------------------------------
This message and any attachment has been virus checked by the
PGRD Sandwich Data Centre.
----------------------------------------------------------------
I work for a leading medical device company and we cannot afford these
licences either.
The prices seem to be aimed at the more affluent pharmaceutical companies!
Jackie Bower
-----Original Message-----
From: Roy Davies [mailto:[log in to unmask]]
Sent: 07 February 2001 09:50
To: [log in to unmask]
Subject: Re: Nature
I wonder who exactly the publishers expect to sign up for
online access? Have they deliberately turned their backs on
the academic market? Obviously large science-based firms
will be able to afford it but it would be interesting to
know how many (if any) universities have decided to
subscribe to the online version.
I suspect that if Nature reduced the price by 90% the
number of academic customers would increase much more
than ten-fold and the publishers would probably earn more
money, even taking into account their increased
administration costs etc.
Roy Davies
University Library
University of Exeter
Stocker Road
Exeter EX4 4PT
UK
PFIZER GLOBAL RESEARCH AND DEVELOPMENT
----------------------------------------------------------------
This message and any attachment has been virus checked by the
PGRD Sandwich Data Centre.
----------------------------------------------------------------
|